Table 1.

Characteristics of the study population (n = 2254). Values are n (%) or mean ± SD.

CharacteristicsValues
Site
  Toronto, ON, Canada1362 (60.5)
  Vancouver, BC, Canada73 (3.2)
  Ann Arbor, MI, USA77 (3.4)
  St. Johns, NL, Canada127 (5.6)
  Rochester, NY, USA295 (13.1)
  London, ON, Canada58 (2.6)
  Winnipeg, MB, Canada181 (8)
  Haifa, Israel81 (3.6)
Disease status
  PsA1327 (58.9)
  Psoriasis927 (41.1)
Age, yrs52 ± 13.8
Male sex1200 (53.2)
Ethnicity
  White1800 (82.4)
  South Asian85 (3.9)
  Chinese59 (2.7)
  Other240 (10.9)
Duration of psoriasis, yrs21.5 ± 15
Duration of PsA, yrs13.7 ± 12.1
Tender joint count*5.14 ± 9.36
Swollen joint count*2.16 ± 5.13
Damaged joint count*4.82 ± 9.96
PASI4.13 ± 5.75
Current use of NSAID922 (40.9)
Current use of DMARD882 (39.1)
Current use of oral corticosteroids91 (4)
Current use of biologics709 (31.5)
  • * In patients with PsA. PsA: psoriatic arthritis; PASI: Psoriasis Area and Severity Index; NSAID: nonsteroidal antiinflammatory drugs; DMARD: disease-modifying antirheumatic drugs